MCL Literature Feed

A systematic review finds MCL has particularly high uptake on CXCR4-targeted [68Ga]Ga-Pentixafor PET, suggesting its utility for staging and response assessment, potentially superior to FDG-PET.

This study confirms a rare DLBCL subtype with CCND1 rearrangement, molecularly distinct from MCL by its SOX11-negativity and DLBCL-like mutations, posing a critical diagnostic and therapeutic challenge.

In the frontline MANTLE-FIRST study, fitness status and time to first progression (PFS1) were identified as key prognostic factors for elderly MCL patients, impacting subsequent outcomes.

In the BRUIN study, relapsed/refractory MCL patients previously treated with a BTKi maintained or improved quality of life and symptoms on pirtobrutinib, supporting its favorable long-term tolerability.

Genomic analysis reveals MCL relapse is driven by pre-existing resistant clones from diagnosis, not new mutations, emphasizing the need for deep upfront responses to eradicate these subclones.

A preclinical multi-modal profiling platform integrating genomics, in vitro drug screening, and PDX models identified personalized therapies for BTKi-relapsed/refractory MCL, guiding treatment beyond single gene alterations.

Pirtobrutinib-tolerant MCL persister cells survive via a reversible TCA cycle metabolic switch, presenting a novel metabolic vulnerability to target and prevent drug resistance.

White-centered retinal hemorrhages (Roth spots) can be the initial presenting sign of an otherwise hidden mantle cell lymphoma, highlighting an important and unusual diagnostic clue for clinicians.

Blastoid or pleomorphic morphology in mantle cell lymphoma is associated with increased primary and acquired resistance to BTK inhibitors, identifying a high-risk population requiring alternative therapeutic strategies.

Optical Genome Mapping identified a rare IGL::CCND1 translocation in a CD23-positive case, revising a CLL diagnosis to MCL and demonstrating OGM's utility for detecting atypical presentations.

This report identifies KMT2A rearrangement as a rare genetic driver in MCL, defining a distinct subtype often associated with aggressive features like blastoid morphology and poor prognosis.

This large, real-world analysis confirms a dismal prognosis (median OS 5.4 months) for MCL patients progressing after CAR-T, establishing a benchmark for future trials in this high-risk population.

This review outlines emerging therapeutic strategies, such as bispecific antibodies and novel agents, for managing mantle cell lymphoma patients who have relapsed after CAR-T cell therapy.

This review explains how tumor microenvironment crosstalk with B-cell receptor signaling promotes MCL survival and BTKi resistance, underscoring the need to target these interactions for improved therapies.

This case report of mantle cell lymphoma presenting solely as a cutaneous nodule in an elderly patient underscores the need to consider lymphoma in atypical skin lesions for accurate diagnosis.

Integrating genomics and spatial proteomics defines three prognostic MCL subtypes, revealing high-risk TP53-mutated tumors are immune-infiltrated yet exhausted, highlighting potential therapeutic vulnerabilities.

A new immunocompetent mouse model co-expressing SOX11 and CCND1 faithfully recapitulates human MCL, providing a crucial platform for studying disease biology and testing novel immunotherapies.

This case report identifies mantle cell lymphoma as a rare cause of secondary thrombotic microangiopathy, diagnosed via kidney biopsy and resolved with chemotherapy, expanding the differential for this complication.

A case report of a TP53-deleted splenic marginal zone lymphoma acquiring a secondary CCND1 rearrangement upon high-grade transformation suggests an alternative pathway to cyclin D1-driven lymphomagenesis.

An albumin nanocomplex of the BCL-2/xL inhibitor APG-1252 reduces thrombocytopenia and enhances anti-MCL efficacy in mouse models, offering a potential strategy to improve the therapeutic window.

A patient-derived organoid model from prostate-metastatic MCL predicted sensitivity to gemcitabine but resistance to rituximab/oxaliplatin, offering a new platform for personalized therapy selection in heterogeneous disease.

This review highlights the diagnostic challenge of distinguishing mantle cell lymphoma with plasmacytic differentiation from multiple myeloma, particularly the CCND1-translocated subtype, emphasizing the need for careful molecular workup.

Long-term follow-up (37.2 months) in Japanese relapsed/refractory MCL patients shows the ibrutinib-venetoclax combination yields durable complete responses (83% CR), high MRD negativity, and a manageable safety profile.

This Delphi consensus provides a framework to overcome CAR-T referral barriers in MCL, emphasizing early patient identification and structured collaboration between centers to improve access and timeliness of therapy.

The Japanese PMDA has approved the BTK inhibitor acalabrutinib for treating mantle cell lymphoma, providing a new therapeutic option for patients in Japan.

This review advocates for integrating BTK inhibitors into frontline MCL therapy for all patients, particularly for TP53-mutated disease, challenging the standard role of chemotherapy.

This first-of-its-kind case report documents mantle cell lymphoma presenting as appendiceal intussusception, highlighting a rare gastrointestinal manifestation to consider in elderly patients with this surgical emergency.

This study evaluates the novel, chemotherapy-free combination of PI3Ki copanlisib and BCL2i venetoclax as a new targeted therapy for patients with relapsed/refractory mantle cell lymphoma.

A pooled analysis of six phase 3 trials shows median overall survival for young, fit MCL patients improved from 4.9 years to not reached, driven by intensified frontline chemoimmunotherapy and transplant.

CT-based radiomics combined with machine learning accurately differentiates MCL from other lymphomas non-invasively, potentially improving diagnostic precision and guiding biopsies in treatment-naïve patients.